Zeba M. Khan

Zeba M. Khan

Auto-generated profile, based on publicly available information

Zeba M. Khan

Zebgene LLC, Malvern, PA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
PLPierre Levy
Pierre Levy
TLTobiasz Lemański
Tobiasz Lemański
CCCatriona Crossan
Catriona Crossan
ALAnna Lefebvre
Anna Lefebvre
JBJean-Baptiste Brière
Jean-Baptiste Brière
ZKZeba M. Khan
Zeba M. Khan
To evaluate the cost-effectiveness of a single-pill combination (SPC) of perindopril/amlodipine/indapamide versus its free equivalent combination (FEC) in adults with hypertension in Italy. A Markov model was developed to perform a cost-utility analysis with a lifetime horizon and an Italian healthcare payer's perspective. In the model the additional effect of the SPC on blood pressure level compared with the FEC was translated into a decreased risk of cardiovascular events and CKD, which was modeled via Framingham risk algorithms. Difference in persistence rates of SPC and FEC were modeled via discontinuation rates. A perindopril/amlodipine/indapamide SPC is associated with lower cost and better health outcomes compared to its FEC. Over a lifetime horizon, it is associated with 0.050 QALY gain and cost savings of €376, resulting from lower cardiovascular event rates. In the alternative scenario, where different approach for modeling impact of adherence was considered, incremental gain of 0.069 QALY and savings of €1,004 were observed. Results were robust to sensitivity and scenario analyses, indicating that use of this SPC is a cost-effective strategy. The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC.

Verified
Journal Article
Open access
ZKZeba M. Khan
Zeba M. Khan
JBJean Baptiste Briere
Jean Baptiste Briere
EOElzbieta Olewinska
Elzbieta Olewinska
FKFatma Khrouf
Fatma Khrouf
MNMateusz Nikodem
Mateusz Nikodem
Background: Heart failure is a chronic disease linked with significant morbidity and mortality, and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic literature review aimed to assess the efficacy, safety, and patient-reported outcomes (PROs) of ivabradine in patients with heart failure (HF) with reduced ejection fraction (HFrEF) in randomized controlled trials (RCTs) and observational studies.

16 July 2024 in Journal of Community Health
Verified
Journal Article
Open access
PDF file
BRBrijesh Rana
Brijesh Rana
HJHumberto R. Jimenez
Humberto R. Jimenez
ZKZeba M. Khan
Zeba M. Khan
NNNavaneeth Narayanan
Navaneeth Narayanan
Backgroud: Socioeconomic status (SES) plays a vital role in determining vaccination uptake and attitudes. Vaccine hesitancy varies among different communities, yet knowledge of vaccine attitudes among Asian-Americans is limited. Objective: This study aims to investigate the relationship between SES and vaccine attitudes among Asian-Americans in the State of New Jersey (NJ). Methods: Asian-Americans aged ≥ 18 years living in NJ were included (N = 157). SES was measured by education level, employment type, employment status, and household income. The primary outcomes were vaccine hesitancy, reluctance, and confidence for COVID-19, influenza, and pneumococcal vaccines. Descriptive and inferential statistics were performed. Multivariable logistic regression was used to identify associations between SES and vaccine hesitancy while controlling for confounders such as age, gender, birthplace, and religion. Results: Among 157 participants, 12.1% reported vaccine hesitancy. There was no statistically significant association between vaccine hesitancy and education level (p = 0.68), employment status (p = 1), employment type (p = 0.48), and household income (p = 0.15). Multivariable logistic regression modeling confirmed that none of the SES predictor variables were associated with vaccine hesitancy. However, as exploratory finding, gender was found to be a significant predictor, with males having lower odds of vaccine hesitancy than females (Adjusted OR = 0.14; p < 0.05). Confidence in influenza and pneumococcal vaccines increased during the pandemic, from 62.34% to 70.13% and from 59.2% to 70.51%, respectively. For the COVID-19 vaccine, 73.1% of participants reported having “a lot of confidence” in taking vaccine. Conclusion: Most sampled Asian-Americans in NJ have high confidence in taking COVID-19 vaccines, and there is no significant association between vaccine hesitancy and SES.

4 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MCMohin Chanpura
Mohin Chanpura
ZKZeba M. Khan
Zeba M. Khan
AAAyse Akincigil
Ayse Akincigil
BACKGROUND HMG-CoA reductase inhibitors (statins) are well-established as an effective pharmacotherapy for dyslipidemia, a condition thought to trigger excess amyloid beta (Aβ) aggregation. Statins may therefore also offer prophylaxis against Alzheimer’s Disease and Related Dementias (ADRD). METHODS To assess associations between statin use and ADRD risk, we conducted a secondary analysis of United States Medicare Current Beneficiary Survey (MCBS) data from 2019-2020. Each respondent with ADRD was matched with two other persons based on key demographic characteristics to create cases and comparisons, making for a total of 3,468 Medicare beneficiaries included in the analysis. Beneficiary ADRD diagnosis statuses were identified using MCBS’s self-reported Health Status and Functioning Questionnaire and/or the Health Status section of the MCBS Facility Instrument. Prescription utilization data, as published in the MCBS PME module, was used to identify statin users and nonusers. Associations between statin use and ADRD diagnosis were assessed via Fisher’s exact tests. FINDINGS Statin utilization was associated with significantly reduced ADRD risk (OR 0.68; p<0.0001). Rosuvastatin was associated with significantly reduced ADRD risk relative to atorvastatin (OR 0.66; p=0.0193). Additionally, hydrophilic statins were associated with significantly reduced ADRD risk relative to lipophilic statins (OR 0.77; p=0.0394). CONCLUSIONS While statin use was found to correlate to significantly reduced ADRD risk, longitudinal research remains necessary to confirm that statins are indeed effective prophylactics against ADRD.